$GNPX's lead product candidate, Oncoprex, consists
Post# of 47054
(Total Views: 154)
Posted On: 09/27/2018 2:58:25 PM
$GNPX's lead product candidate, Oncoprex, consists of a TUSC2 gene encapsulated in a positively charged nanovesicle made from lipid molecules with a positive electrical charge. Oncoprex is injected intravenously and can specifically target cancer cells, which generally have a negative electrical charge. Once Oncoprex is taken up into a cancer cell, the TUSC2 gene is expressed into a protein that is capable of restoring certain defective functions arising in the cancer cell. https://www.genprex.com/technology
(0)
(0)Scroll down for more posts ▼